News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News February 4, 2026
Advised BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics
Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc.
Client Alert February 3, 2026
Corporate Resolutions 2025 Year-End Update
This update analyzes corporate criminal enforcement in 2025 by the numbers and in context of the new United States Presidential Administration’s …
Client Alert January 27, 2026
False Claims Act 2025 Year-End Update
This update covers recent developments in FCA jurisprudence, summarizes significant enforcement activity, and analyzes the most notable legislative, policy, and …
Webcasts November 13, 2025
Webcast: FCA Enforcement Across Administration Priorities: New Frontiers and Interagency Collaboration
Join Gibson Dunn lawyers in this recorded webcast as they analyze key developments in FCA enforcement related to DEI, trade, cybersecurity, and health care and offer practical considerations for companies across the range of industries for which the FCA is increasingly relevant.
Firm News October 28, 2025
Gibson Dunn Advised BVP Forge on Investment in Strategic Combination of Sunwave Health and Lightning Step
Gibson Dunn advised BVP Forge on its investment in the strategic combination of Sunwave Health and Lightning Step to form a unified technology platform, purpose-built for behavioral health providers nationwide
Client Alert September 8, 2025
Getting Serious About Tariff Evasion – New Trade Fraud Task Force Continues Trend of DOJ’s Top-Down Generation of Investigative Targets
The Trade Fraud Task Force seeks to enhance information sharing between DOJ civil and criminal prosecutors, Customs and Border Protection, and Homeland Security Investigations to identify instances of customs fraud for DOJ to pursue as civil and criminal enforcement actions.
Firm News September 4, 2025
Gibson Dunn Advises Arrowhead Pharmaceuticals on Global Licensing and Collaboration Agreement with Novartis
Gibson Dunn is advising Arrowhead Pharmaceuticals on its global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical-stage siRNA therapy targeting alpha-synuclein for the treatment of synucleinopathies, as well as for additional collaboration targets utilizing Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform
Client Alert July 14, 2025
False Claims Act 2025 Mid-Year Update
Gibson Dunn is monitoring these developments, along with other FCA legislative activity, settlements, and jurisprudence throughout the year and report back in our 2025 False Claims Act Year-End Update.